BeOne Medicines Expands U.S. Cancer Access and Manufacturing
SAN CARLOS, Calif., August 31, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company,...
Cancer Treatment
Advertisement
Karmanos Offers FDA-Approved Daraxonrasib for Cancer
Detroit, Michigan, August 31, 2026 The Barbara Ann Karmanos Cancer Institute announced that it is now offering FDA-approved daraxonrasib...
Lilly’s Taltz and Zepbound Show One-Year Benefits
Indianapolis, Indiana, August 31, 2026 Eli Lilly and Company announced new Phase 3b data showing that treatment with Taltz®...
RedHill Divests Talicia to Apotex for $18 Million
Miami, Florida, August 31, 2026 RedHill Biopharma Ltd. announced that it has entered into an agreement to divest Talicia®...
IDEAYA’s IDE849 Advances Toward Phase 3 in Lung Cancer
South San Francisco, California, August 31, 2026 IDEAYA Biosciences, Inc. announced the successful completion of a U.S. Food and...
Advertisements
Jazz Reports Survival Benefit for Ziihera in GEA
Dublin, Ireland, August 31, 2026 Jazz Pharmaceuticals plc announced positive topline results from the Phase 3 HERIZON-GEA-01 clinical trial,...
Roivant Wins FDA Approval for LISRAYA in Dermatomyositis
Basel, Switzerland, London, United Kingdom & New York – August 27, 2026 Roivant announced that the U.S. Food and...
HUTCHMED Wins NMPA Approval for ATLED in ICC
Hong Kong, Shanghai & Florham Park, New Jersey – August 28, 2026 HUTCHMED announced that China’s National Medical Products...
Zymeworks Wins FDA Approval for Ziihera in HER2+ GEA
VANCOUVER, British Columbia – August 25, 2026 Zymeworks Inc. announced that its partner Jazz Pharmaceuticals has received U.S. FDA...
RenovoRx Expands RenovoCath Patent Protection for Cancer
Mountain View, California, U.S. | August 20, 2026 RenovoRx announced that the U.S. Patent and Trademark Office (USPTO) has...
Advertisement
